Cas:17608-52-5 4-O-Caffeoyl-quinic acid manufacturer & supplier

Chemical Name:4-O-Caffeoyl-quinic acid

CAS.NO:17608-52-5

Synonyms:4-O-Caffeoyl-quinic acid

Molecular Formula:C₁₆H₁₈O₉

Molecular Weight:354

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-O-Caffeoyl-quinic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-O-Caffeoyl-quinic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-O-Caffeoyl-quinic acid Use and application,4-O-Caffeoyl-quinic acid technical grade,usp/ep/jp grade.

Related News: FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. 4-O-Caffeoyl-quinic acid manufacturer The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 4-O-Caffeoyl-quinic acid supplier Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. 4-O-Caffeoyl-quinic acid vendor The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively). 4-O-Caffeoyl-quinic acid factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.